Alpha MSH in Ocular Disease

The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease. Alpha MSH has been shown to have an important role in the regulation of ocular immunity in animal models of inflammatory retinal diseases and retinal dystrophies, and there may be a protective effect of alpha MSH. By studying the levels of alpha MSH in your eye we may better understand its role in advanced dry macular degeneration. By studying the levels of this molecule we hope to better understand if it may be a good target for future treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Advanced Dry Macular Degeneration Blindness Eye Diseases Macular Degeneration Nervous System Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Retinal Degeneration Retinal Diseases Sensation Disorders Signs and Symptoms Vision Disorders

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Duke University Eye Center

Durham, North Carolina, 27710, United States

About this study

A small amount (0.1 mL) of aqueous humor would be removed from the study eye in the clinic setting. This sample will be processed and then sent off for measurement of alpha MSH levels.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

60 years or older
diagnosis of advanced dry macular degeneration with foveal geographic atrophy
limited vision or blindness (20/100 or worse) in that eye
pseudophakia (prior cataract surgery in that eye)

Exclusion criteria

Treatment and study plan

Alpha MSH assay

Device

Assay to detect levels of alpha MSH in intraocular fluid.

Primary outcomes

Level of Alpha Melanocyte Stimulating Hormone as Measured by Enzyme-linked Immunosorbent Assay

Time frame: 2 hours

Sponsors and collaborators

Lead sponsor

Duke University

Other

Registry information

Official study title

The Role of Alpha Melanocyte Stimulating Hormone in Ocular Disease

Important dates

Study start: 2018
Primary completion: 2021
Study completion: 2021
First posted: Mar 1, 2018
Registry last updated: Dec 22, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed